tbuckley/cabot-search huggingface dataset:
Bcl-xl downregulation using short hairpin RNA (shRNA) sensitises HCT-116 colon cancer cells to topoisomerase I inhibition
Authors: Cagla Akay, Fatih Kircelli, Yair Gazitt
Journal: Cancer Research (2005)

5343   Bcl-xl is an anti-apoptotic protein from the bcl-2 family, overexpressed in 40-80% of colorectal cancer, which has been implicated in drug resistance. Downregulation of bcl-xl may increase the sensitivity to anticancer agents by allowing cells to undergo apoptosis. ShRNAs targeting bcl-xl were expressed in HCT-116 cells and G-418 resistant populations selected. Bcl-xl and bcl-2 mRNA levels were determined by qRT-PCR and results normalised by 18S expression. In stable transfectants expressing shRNA#3 (HCT-116 shxl3) and shRNA#4 (HCT-116 shxl4), a downregulation of bcl-xl was observed: bcl-xl/18S = 0.4 ± 0.03 and 0.5 ± 0.03, respectively compared to cells expressing the empty vector (HCT116 NG) in which bcl-xl/18S = 1 ± 0.09. Bcl-2 was also downregulated in HCT-116 shxl3: bcl-2/18S = 0.4 ±0.03 compared to HCT116 NG (1.1 ± 0.1). The cytotoxic effect of topoisomerase I inhibitors SN-38 and CPT and also the topoisomerase II inhibitor doxorubicin was evaluated. Both HCT-116 shxl3 and 4 were more sensitive to SN-38 (IC50: 2.2 and 2.1 nM, respectively vs 3.2 nM in HCT-116 NG cells) and CPT (IC50: 5.2 and 6.1 nM, respectively vs 8.3 nM for HCT-116 NG cells) but equally sensitive to doxorubicin (IC50: 24 and 26 nM, respectively vs 27 nM in HCT-116 NG cells). The cytotoxicity of antimycin A3, a small molecule inhibitor of bcl-xl was also determined: HCT-116 shxl3 and 4 showed increased sensitivity (IC50: 0.33 and 0.50 μM) compared to HCT-116 NG (IC50: 0.97 μM). Decrease in membrane permeability potential evaluated by JC-1 staining was greater in HCT-116 shxl3 following exposure to SN-38: JC-1 red fluorescence decreased by 51% compared to 42% in HCT-116 NG cells. HCT-116 NG and HCT116 shxl3 were established  in vivo  as xenografts in immunodeficient Nu/Nu mice. When tumours reached 50-100 mm 3 , animals were treated with CPT-11 25 mg/kg dx5. Tumour growth inhibition was greater in HCT-116 shxl3 (median doubling time, 14 days) compared to HCT-116 NG xenografts (median doubling time, 10 days). This delay was sustained: Median time to reach five times the initial tumour volumes was 25.5 days for HCT-116 shxl3 vs 20 days for HCT-116 NG xenografts. Downregulation of bcl-xl and bcl-2 using shRNA in HCT-116 cells sensitised cells, both  in vitro  and  in vivo , to the topoisomerase I inhibitor SN-38. Increased loss of mitochondrial permeability potential was noted  in vitro  and ongoing experiments will confirm if this mechanism is also relevant  in vivo .
Maryland’s Hospital Global Budget Program—Reply
Authors: Joshua M. Sharfstein, Elizabeth A. Stuart, Joseph Antos
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Long term outcomes of preoperative concurrent CapeOx/RT in locally advanced rectal cancer
Authors: E. Sirachainan, C. Sitathanee, W. Suwanthanma, N. Larbcharoensub, S. Lukrak, N. Sripaiboonkit Thokanit, S. Phongkitkarun, K. Sumboonnanonda
Journal: Annals of Oncology (2018)
Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic Alterations
Authors: Michael T. Tetzlaff, Jonathan L. Curry, Jing Ning, Oded Sagiv, Thomas L. Kandl, Bo Peng, Diana Bell, Mark Routbort, Courtney W. Hudgens, Doina Ivan, Tae-Boom Kim, Ken Chen, Agda Karina Eterovic, Kenna Shaw, Victor G. Prieto, Anna Yemelyanova, Bita Esmaeli
Journal: Clinical Cancer Research (2018)

Ocular adnexal (OA) sebaceous carcinoma is an aggressive malignancy of the eyelid and ocular adnexa that frequently recurs and metastasizes, and effective therapies beyond surgical excision are lacking. There remains a critical need to define the molecular-genetic drivers of the disease to understand carcinomagenesis and progression and to devise novel treatment strategies.We present next-generation sequencing of a targeted panel of cancer-associated genes in 42 and whole transcriptome RNA sequencing from eight OA sebaceous carcinomas from 29 patients.We delineate two potentially distinct molecular-genetic subtypes of OA sebaceous carcinoma. The first is defined by somatic mutations impacting TP53 and/or RB1 [20/29 (70%) patients, including 10 patients whose primary tumors contained coexisting TP53 and RB1 mutations] with frequent concomitant mutations affecting NOTCH genes. These tumors arise in older patients and show frequent local recurrence. The second subtype [9/29 (31%) patients] lacks mutations affecting TP53, RB1, or NOTCH family members, but in 44% (4/9) of these tumors, RNA sequencing and in situ hybridization studies confirm transcriptionally active high-risk human papillomavirus. These tumors arise in younger patients and have not shown local recurrence.Together, our findings establish a potential molecular-genetic framework by which to understand the development and progression of OA sebaceous carcinoma and provide key molecular-genetic insights to direct the design of novel therapeutic interventions.
Induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma in adults: Results from a non-endemic cohort of South India
Authors: T. Chaudhuri, K.C. Lakshmaiah, K.G. Babu, L. Dasappa, L.A. Jacob, M.C.S. Babu, K.N. Lokesh, A.H. Rudresha, L.K. Rajeev, R. Patidar, V. Asati, R. Chethan, D. Koppaka, A. Anand
Journal: Annals of Oncology (2018)
A first-in-human trial of RG7116, a glycoengineered monoclonal antibody targeting HER3, in patients with advanced/metastatic tumors of epithelial cell origin expressing HER3 protein.
Authors: Didier Meulendijks, Martijn P. J. K. Lolkema, Emile E. Voest, Maja J. De Jonge, Stefan Sleijfer, Jan HM Schellens, Tania Fleitas, Andres Cervantes-Ruiperez, Maria Martinez-Garcia, Alvaro Taus, Morten Mau Soerensen, Marlene Thomas, Georgina Meneses-Lorente, Celine Adessi, Lilla Di Scala, Abiraj Keelara, Wolfgang Jacob, Martin Weisser, Ulrik Niels Lassen
Journal: Journal of Clinical Oncology (2013)

2522 Background: The Human Epidermal Growth Factor Receptor 3 (HER3) is a key heterodimerization partner for other HER family members thereby acting as a downstream signal amplifier. This is a first in human study evaluating the safety of RG7116, a humanized anti-HER3 monoclonal antibody with potent HER3 signal inhibition. Due to a glycoengineered Fc-part this antibody displays enhanced antibody-dependent cellular cytotoxicity as compared to conventional antibodies. Methods: Patients (pts) with advanced or metastatic carcinomas with centrally confirmed HER3 protein expression were included. A “3+3” dose escalation design was performed starting at 100 mg flat dosing in a q2w regimen. In addition to single agent RG7116 (Part A), RG7116 plus cetuximab (Part B) and RG7116 plus erlotinib (Part C) combinations are evaluated. The results of Part A are presented. Results: Twenty-five pts have been enrolled in 6 cohorts (100 to 2000 mg). No DLTs were observed. Pts had a median (range) of 3 (2 to 6) prior chemotherapy lines. Nine infusion-related reactions (IRRs) Gr 1 to 3 occurred in 7 pts. Three drug-related AEs Gr 3 were reported, 1 IRR, 1 GGT increase, and 1 neutropenia. Only 1 patient was tested positive for human anti human antibodies (HAHA). The PK of RG7116 was non-linear from 100 mg up to 400 mg, possibly as a result of target-mediated drug disposition. Both C max and AUC showed a greater than doseEproportional increase over the same dose range, accompanied by a decline in total clearance. Dose proportionality was observed from 800 mg onwards. PD effects were observed from the first dose level onwards with HER3 membranous protein down-regulation in skin and from 200 mg onwards in ontreatment tumor samples. Five pts (1 NSCLC, 2 CRC, 1 SCCHN, 1 BC) had a best response of SD. Confirmed SD (&gt;16 weeks) was observed in 2 pts. One BC patient achieved a PR in 18 FDG-PET and significant shrinkage of non-target tumor lesions on CT scan. Conclusions: RG7116 is the first glycoengineered monoclonal anti-HER3 antibody in clinical development. RG7116 monotherapy was well tolerated, and demonstrated preliminary signs of clinical activity. Clinical trial information: NCT01482377.
Phase II study of nedaplatin plus amrubicin in patients with untreated, advanced or relapsed squamous cell lung cancer
Authors: T. Suyama, H. Taniguchi, T. Ikeda, H. Yamaguchi, T. Kitazaki, H. Soda, K. Nakatomi, A. Kinosita, M. Fukuda, H. Mukae
Journal: Annals of Oncology (2018)
Effects of deferasirox dose and decreasing serum ferritin concentrations on kidney function in paediatric patients: an analysis of clinical laboratory data from pooled clinical studies
Authors: Steven T Bird, Richard S Swain, Fang Tian, Olanrewaju O Okusanya, Peter Waldron, Mona Khurana, Elizabeth L Durmowicz, Yong Ma, Jacqueline M Major, Kate Gelperin
Journal: The Lancet Child & Adolescent Health (2018)
Abstract P173: Hyperthyroidism Increases the Risk of Takotsubo Cardiomyopathy Among Hospitalized US Patients
Authors: Akintunde M Akinjero, Oluwole Adegbala, Tomi Akinyemiju
Journal: Circulation (2017)

Background: The association between hyperthyroidism and Takotsubo Cardiomyopathy (TTCM) has only been reported in isolated case reports and a recent single center study with inconclusive results. It is known that elevated thyroid hormone causes an increased sympathetic modulation of heart rate. It has also been shown that TTCM occurs in the setting of acute stressful illnesses involving excess catecholamine release. What is unclear is whether hyperthyroid states can predispose to TTCM. This is the first nationwide study of this association. Methods: We used ICD-9 CM codes to extract data from the Nationwide Inpatient Sample database from 2007-2011. Patients with TTCM and coexisting hyperthyroidism were compared with TTCM patients without coexisting hyperthyroidism. We excluded persons below the age of 18 as well as patients diagnosed with TTCM who later underwent percutaneous coronary intervention (PCI). Multivariate logistic regression was used to assess the independent effect of coexisting hyperthyroidism on the occurrence of TTCM. Results: A total of 33,639,230 patients were included, where 123,923 patients had hyperthyroidism while 32,400,000 did not have hyperthyroidism. There were 101 (0.08%) TTCM patients with coexisting hyperthyroidism compared to 13,893 (0.04%) without (p&lt;0.0001). In adjusted models, patients with hyperthyroidism had a higher risk of TTCM in the index hospital admission (aOR=1.43, 95% CI=1.18-1.74), independent of potential demographic, comorbid and lifestyle confounders. Hispanics with hyperthyroidism had the highest risk of TTCM (OR=1.41, 95% CI=1.39-1.44). Conclusion: In this large, nationwide study, hyperthyroidism was associated with increased risk of TTCM. This association was strongest among hispanics. Further research is needed to understand the mechanisms behind this association.
Abstract 18934: Clinical Trial Strategies for Identifying an Evolocumab and Inclisiran Combination Regimen With Improved Safety and Efficacy Over Evolocumab Alone
Authors: Thomas R Roesel
Journal: Circulation (2017)

Introduction: Evolocumab monoclonal antibody trials demonstrated safety and efficacy in lowering elevated LDL cholesterol (LDL-C) to a median of 48 mg/dL. Cardiovascular events (CVE) were decreased...
User-Centered Redesign of Evidence-Based Psychosocial Interventions to Enhance Implementation—Hospitable Soil or Better Seeds?
Authors: Aaron R. Lyon, Eric J. Bruns
Journal: JAMA Psychiatry (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
OP0235 Interferon-free antivirals for hepatitis c virus-associated cryoglobulinemia vasculitis: a long-term follow-up study
Authors: P. Cacoub, S.N. Si ahmed, Y. ferfar, S. Pol, D. Thabut, C. Hezode, L. Alric, C. Comarmond, G. Ragab, L. Quatuccio, M. Hegazy, T. Poynard, M. Resche Rigon, D. Saadoun
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> In small-size and short term studies of hepatitis C virus (HCV)-cryoglobulinemia vasculitis (CryoVas), direct antiviral agents (DAAs) showed a better response rate and tolerance than interferon containing regimens. <h3>Objectives</h3> To evaluate the effectiveness and tolerance of all oral interferon-free DAA in a large CryoVas cohort with long-term follow-up. <h3>Methods</h3> This prospective international multicenter cohort study included 148 symptomatic HCV-CryoVas patients (53.7% with cirrhosis and 49.3% antiviral-naïve). They all received DAA, i.e. sofosbuvir (SOF) plus daclatasvir (n=53), SOF plus ribavirin (n=51), SOF plus ledipasvir (n=23), or SOF plus simeprevir (n=18), for 12 or 24 weeks. The primary endpoint was the clinical response of CryoVas symptoms at week 12 after stopping DAAs. <h3>Results</h3> 106 (72.6%) patients showed a complete response, 33 (22.6%) a partial response and 7 (4.8%) no response of CryoVas symptoms. Cryoglobulinemia was no longer found in 53.1%. A sustained virological response was obtained in 97.2%. Premature DAA withdrawal was noted in 4.1%. Two factors were associated with a poor response: a severe form of CryoVas [OR 0.33, 95% CI: 0.12 to 0.91; p=0.03] and peripheral neuropathy [OR 0.31, 95% CI: 0.11 to 0.84; p=0.02]. After a median follow-up of 15.3 months, 4 (2.8%) patients died. The final clearance rates of CryoVas manifestations were as follows: purpura (97.2%), renal involvement (91.5%), arthralgia (85.7%), neuropathy (77.1%) and cryoglobulinemia (53.8%). Only SOF plus ledipasvir regimen showed significant superiority [OR 4.09, 95% CI: 1.19 to 19.00; p=0.04]. <h3>Conclusions</h3> The different DAA combinations showed high response rates of HCV-CryoVas symptoms. The tolerance was good, and the mortality rate was very low. We identified prognosis factors of response to DAA. <h3>Disclosure of Interest</h3> P. Cacoub Consultant for: Janssen, BMS, Abbvie, GSK, Astra zeneka, Gilead, Merck, Roche, Servier, Vifor, S. N. Si ahmed Consultant for: BMS, Abbvie, Gilead, Roche, Janssen, Y. ferfar: None declared, S. Pol Consultant for: Sanofi, Novartis, Vertex, Boehringer, Janssen, BMS, Abbvie, GSK, Astra zeneka, Gilead, Merck, Roche, Servier, Vifor, D. Thabut: None declared, C. Hezode Consultant for: BMS, Merck, Abbvie, Gilead, Roche, Janssen, L. Alric Consultant for: BMS, Abbvie, Gilead, Janssen, Merck, C. Comarmond: None declared, G. Ragab: None declared, L. Quatuccio: None declared, M. Hegazy: None declared, T. Poynard: None declared, M. Resche Rigon: None declared, D. Saadoun Consultant for: medimmune, BMS, Abbvie, GSK, Astra zeneka, Gilead, Merck, Roche, Servier,
Interpreting the Long-term Prognostic Value of Total Mesorectal Excision Plane Quality in Rectal Adenocarcinoma
Authors: Ryan Sun, Hwajeong Lee, Lee-Jen Wei
Journal: JAMA Surgery (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
A Wide Complex Tachycardia in a Woman During Exercise
Authors: Anoop Muniyappa, Arun Padmanabhan, Nora Goldschlager
Journal: JAMA Internal Medicine (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Antihunger Groups Are Blocking Nutrition Progress in the Supplemental Nutrition Assistance Program
Authors: Sara N. Bleich, Mary T. Gorski Findling, Jason P. Block
Journal: JAMA Pediatrics (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
AB0660 The role of anti-neutrophil cytoplasmic autoantibody specificity for mpo or pr3 in phenotype of anca associated vasculitis: knowing the autoimmunity in latin america
Authors: E. Calle, M. Calle, H.B. Cabrera, D. Jaramillo-Arroyave, A.L. Vanegas-García, G. Vásquez-Duque, M. Restrepo-Escobar, L.A. González-Naranjo, J. Hernández-Zapata, C.H. Muñoz-Vahos
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Antineutrophil cytoplasmic antibodies (ANCA) are present in up to 90% granulomatosis with polyangiitis, 80% microscopic polyangiitis and 70% eosinophilic granulomatosis with polyangiitis. MPO-ANCA has been associated with vasculitis limited to the kidney, chronic renal damage and less frequent gastrointestinal or respiratory tract involvement. PR3-ANCA are characterised by destructive lesions of the ears, nose and throat, alveolar haemorrhage, combination of upper and/or lower respiratory tract involvement with renal compromise and increased number of relapses. The frequency of pulmonary involvement is similar in both serotypes, and most ANCA associated vasculitis (AAV) patients are diagnosed between ages 50 and 70 years. <h3>Objectives</h3> To describe differences in clinical profiles of patients with AAV regarding ANCA specificity against MPO or PR3 in a Colombian based adult population <h3>Methods</h3> All medical records of patients with a diagnosis of AAV in two high complexity hospitals in Medellín, Colombia from January 1, 2014 to December 31, 2016 were reviewed. The clinical and demographic characteristics were abstracted and analysed with descriptive and inferential statistics in SPSS.22 <h3>Results</h3> Of 59 cases of AAV, 44 were positive for MPO or PR3-ANCA with male predominance (65.5% men vs 34.5% women) and similar age at diagnosis (47 years in MPO-ANCA vs 50 in PR3-ANCA). MPO-ANCA group had more fever and weight loss (34.8% vs 20%), arterial hypertension (34.5% vs 26.7%), hematuria (34.5% vs 26.7%), proteinuria (31% vs 26.7%), creatinin higher than 5.6 mg/dL (20.7 vs 13.3%), myalgias (13.8 vs 0%) pachymeningitis (7% vs 0%) and skin compromise. PR3-ANCA patients had more arthralgias/arthritis (40% vs 31%), escleritis (33% vs 13.8%), episcleritis (13.3% vs 0%) and uveítis (10% vs 7%). <h3>Conclusions</h3> In this Latin American population ANCA specificity affected the phenotype of clinical disease. MPO-ANCA patients had more constitutional symptoms, renal and central nervous system compromise while PR3-ANCA patients showed more articular and ocular involvement. <h3>References</h3> [1] Cornec D, et al. Nat Rev Rheumatol. 2016Oct;12(10):570–9. [2] Hilhorst M, et al. J Am Soc Nephrol. 2015Oct;26(10):2314–27. [3] Lionaki S, et al. Arthritis Rheum. 2012Oct;64(10):3452–62. [4] Savige J, et al. Best Pract Res Clin Rheumatol. 2005Apr;19(2):263–76. [5] Schirmer JH, et al. Arthritis Rheumatol. 2016Dec;68(12):2953–2963. <h3>Disclosure of Interest</h3> None declared